首页 | 本学科首页   官方微博 | 高级检索  
检索        

基于EPID在体三维剂量验证系统的物理模型测试及初步临床探索
引用本文:毛荣虎,郭伟,李兵,张永,王庆杰,程秀艳,葛红,雷宏昌.基于EPID在体三维剂量验证系统的物理模型测试及初步临床探索[J].中华放射肿瘤学杂志,2021,30(10):1065-1070.
作者姓名:毛荣虎  郭伟  李兵  张永  王庆杰  程秀艳  葛红  雷宏昌
作者单位:郑州大学附属肿瘤医院 河南省肿瘤医院放疗科 450008
基金项目:河南省科技项目(162102310321)
摘    要:目的 使用模体验证基于电子射野影像装置(EPID)在体三维剂量验证建模的准确性,并进行临床应用的初步研究。方法 通过方野和调强计划在均匀和非均匀模体上检测EPID在体三维剂量验证系统应用于不同介质中的剂量计算精度和重建精度,比较不同剂量/距离一致性标准下的γ通过率。对临床病例进行靶区和危及器官剂量体积分析。结果 方野在均匀模体中3%/3mm标准平均γ通过率为(97.49±1.11)%,在非均匀模体中为(94.06±5.11)%(P>0.05)。不同出束方式的调强计划之间也相近(P>0.05)。临床病例疗前剂量验证3%/2mm标准γ通过率为(97.96±1.84)%,在体三维剂量验证3%/3mm标准为(90.51±6.96)%。临床病例中小体积和体积变化较大的危及器官有较大剂量偏差。结论 基于EPID建立的在体三维剂量验证模型,经初步测试可应用于临床提供更全面的质量保证,为以后自适应放疗工作提供了技术保障。

关 键 词:电子射野影像装置  在体剂量验证  γ通过率  
收稿时间:2020-07-21

Preliminary study of physical model test and clinical application based on EPID-based in-vivo dose verification system
Mao Ronghu,Guo Wei,Li Bing,Zhang Yong,Wang Qingjie,Cheng Xiuyan,Ge Hong,Lei Hongchang.Preliminary study of physical model test and clinical application based on EPID-based in-vivo dose verification system[J].Chinese Journal of Radiation Oncology,2021,30(10):1065-1070.
Authors:Mao Ronghu  Guo Wei  Li Bing  Zhang Yong  Wang Qingjie  Cheng Xiuyan  Ge Hong  Lei Hongchang
Institution:Department of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China
Abstract:Objective To validate the accuracy of physical model of in-vivo 3D dose verification based on electronic portal imaging device (EPID) using the phantom and preliminarily analyze the clinical application. Methods Two phantoms (uniform and non-uniform phantoms) were involved in this study. The system of in-vivo 3D dose verification based on EPID was employed to acquire the images of square fields (SF) and combined fields of intensity-modulated radiotherapy (CFIMRT). The physical model of different media was constructed using the system. The factor of γ passing rate under different dose/distance criteria was statistically compared. For clinical cases, the dose-volume histograms were adopted to analyze the dose distribution of target volume and organs at risk (OARs). Results For the SF in the uniform phantom, the average γ passing rate (3%/3mm) was (97.49±1.11)%, and (94.06±5.11)% for the SF in the non-uniform phantom (P>0.05). No statistical significance was noted in IMRT using different delivery methods (all P>0.05). For clinical cases, the average γ passing rate (3%/2mm) was (97.96±1.84)% in the pre-treatment dose verification, and (90.51±6.96)%(3%/3mm) for the in-vivo 3D dose verification. For clinical cases, significant dose deviation was observed in OARs with small size and large volume changes. Conclusion The in-vivo 3D dose verification model based on EPID can be effectively applied in inter-fraction dose verification, providing technical support for adaptive radiotherapy in clinical practice.
Keywords:Electronic portal imaging device  In-vivo dose verification  γ passing rate  
点击此处可从《中华放射肿瘤学杂志》浏览原始摘要信息
点击此处可从《中华放射肿瘤学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号